Feb 24, 2026Estrogen, Menopause, and Aging: Hormonal Mechanisms, Health Implications, and ProtocolMenopause-associated estrogen decline drives accelerated changes in cardiovascular risk, bone density, cognitive function, and metabolic health. Menopausal hormone therapy (MHT) has RCT and observational evidence supporting benefits for symptomatic relief and bone protection; cardiovascular and breast cancer risks depend on timing, type, and route of administration.
Feb 24, 2026Testosterone Decline in Men: Natural Trajectory, Functional Impact, and Evidence-Based SupportTestosterone declines approximately 1-2% per year from age 30. The clinical significance of this decline depends on absolute levels and symptoms, not chronological age alone. Testosterone replacement therapy has RCT evidence for improving muscle mass, bone density, and sexual function in men with confirmed hypogonadism. Lifestyle factors significantly modify the trajectory.
Feb 24, 2026Testosterone Decline in Aging Men: Natural Interventions, Monitoring, and TRT ContextTestosterone declines ~1% per year after age 30 in men. Below clinical thresholds, symptoms include fatigue, sarcopenia, and cognitive fog. Lifestyle interventions (resistance training, sleep, zinc, vitamin D) have the best evidence for supporting endogenous production. Ashwagandha and fenugreek show modest RCT data.
Feb 21, 2026Longevity Protocol for Women Over 50: Evidence-Based PrioritiesPerimenopause and post-menopause mark a major metabolic and hormonal inflection point. This protocol covers the highest-leverage interventions for women over 50, grounded in current evidence.
Feb 10, 2026Sex Differences in Supplement Response: Iron, Creatine, Hormonal Context, and What Research ShowsBiological sex affects supplement needs and responses in meaningful ways. Iron requirements differ substantially. Creatine response patterns differ between sexes. Hormonal context (menstrual cycle, menopause, testosterone) affects supplement efficacy and safety profile.